MX2021012984A - Anticuerpos y metodos para el tratamiento de la infeccion por influenza a. - Google Patents

Anticuerpos y metodos para el tratamiento de la infeccion por influenza a.

Info

Publication number
MX2021012984A
MX2021012984A MX2021012984A MX2021012984A MX2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A
Authority
MX
Mexico
Prior art keywords
antibodies
influenza
infection
treatment
methods
Prior art date
Application number
MX2021012984A
Other languages
English (en)
Spanish (es)
Inventor
Davide Corti
Fabio Benigni
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of MX2021012984A publication Critical patent/MX2021012984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021012984A 2019-04-30 2020-04-30 Anticuerpos y metodos para el tratamiento de la infeccion por influenza a. MX2021012984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/061134 WO2020221450A1 (en) 2019-04-30 2019-04-30 Antibodies and methods for treatment of influenza a infection
PCT/EP2020/062160 WO2020221908A1 (en) 2019-04-30 2020-04-30 Antibodies and methods for treatment of influenza a infection

Publications (1)

Publication Number Publication Date
MX2021012984A true MX2021012984A (es) 2021-12-10

Family

ID=66429359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012984A MX2021012984A (es) 2019-04-30 2020-04-30 Anticuerpos y metodos para el tratamiento de la infeccion por influenza a.

Country Status (17)

Country Link
US (1) US20220226470A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962530A1 (cg-RX-API-DMAC7.html)
JP (1) JP7719725B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220003000A (cg-RX-API-DMAC7.html)
CN (2) CN119192357A (cg-RX-API-DMAC7.html)
AU (1) AU2020265407B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021018409A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132536A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002807A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021012583A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192923A1 (cg-RX-API-DMAC7.html)
IL (1) IL287423A (cg-RX-API-DMAC7.html)
MX (1) MX2021012984A (cg-RX-API-DMAC7.html)
PH (1) PH12021552176A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109683TA (cg-RX-API-DMAC7.html)
TW (1) TW202106707A (cg-RX-API-DMAC7.html)
WO (2) WO2020221450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
IL290752B2 (en) * 2019-08-29 2026-02-01 Vir Biotechnology Inc Preparations and methods for treating influenza a infection
US20230340083A1 (en) * 2020-12-08 2023-10-26 Vir Biotechnology, Inc. Antibodies and methods for treatment of influenza a infection
CN112812095A (zh) * 2021-01-29 2021-05-18 成都安满生物医药科技有限公司 一种巴洛沙韦酯中间体的合成方法
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
CN115777944B (zh) * 2023-02-10 2023-05-12 北京衡美金叶营养健康科技有限公司 增强身体防御力的组合物及其制备方法和应用
WO2025024541A2 (en) * 2023-07-24 2025-01-30 University Of Miami Aav-delivered antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
CN103282385A (zh) 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
ES2664095T3 (es) 2012-12-07 2018-04-18 Pfizer Inc. Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética
SG11201602522VA (en) * 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
JP2019502715A (ja) * 2016-01-13 2019-01-31 メディミューン,エルエルシー A型インフルエンザを治療する方法

Also Published As

Publication number Publication date
US20220226470A1 (en) 2022-07-21
CL2021002807A1 (es) 2022-08-19
WO2020221450A1 (en) 2020-11-05
WO2020221908A1 (en) 2020-11-05
CA3132536A1 (en) 2020-11-05
AU2020265407A1 (en) 2021-10-07
JP2022531556A (ja) 2022-07-07
KR20220003000A (ko) 2022-01-07
CN119192357A (zh) 2024-12-27
CO2021012583A2 (es) 2021-10-20
BR112021018409A2 (pt) 2021-11-23
TW202106707A (zh) 2021-02-16
PH12021552176A1 (en) 2022-09-12
CN114269381A (zh) 2022-04-01
JP7719725B2 (ja) 2025-08-06
SG11202109683TA (en) 2021-11-29
AU2020265407B2 (en) 2026-01-08
EA202192923A1 (ru) 2022-02-16
EP3962530A1 (en) 2022-03-09
IL287423A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
ECSP19009170A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
CL2021002307A1 (es) Uso de virus oncolíticos para el tratamiento del cáncer
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CO2024007674A2 (es) Anticuerpo anti-trem2 y usos del mismo
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.